Alpine Immune Sciences Inc (NASDAQ:ALPN) Short Interest Down 27.4% in November

Share on StockTwits

Alpine Immune Sciences Inc (NASDAQ:ALPN) was the recipient of a significant decrease in short interest during the month of November. As of November 29th, there was short interest totalling 12,700 shares, a decrease of 27.4% from the November 14th total of 17,500 shares. Currently, 0.2% of the company’s shares are sold short. Based on an average daily volume of 24,400 shares, the days-to-cover ratio is presently 0.5 days.

Several equities research analysts have commented on ALPN shares. Piper Jaffray Companies dropped their price target on Alpine Immune Sciences to $8.00 and set an “overweight” rating for the company in a research note on Wednesday, November 13th. They noted that the move was a valuation call. Zacks Investment Research upgraded Alpine Immune Sciences from a “hold” rating to a “buy” rating and set a $3.25 price target for the company in a research note on Friday, December 6th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $9.31.

Shares of NASDAQ ALPN traded up $0.07 on Thursday, hitting $3.68. The company had a trading volume of 1,310 shares, compared to its average volume of 20,267. Alpine Immune Sciences has a 12-month low of $2.25 and a 12-month high of $8.24. The business has a 50 day moving average of $2.95 and a two-hundred day moving average of $3.88. The company has a quick ratio of 3.84, a current ratio of 3.84 and a debt-to-equity ratio of 0.47. The firm has a market capitalization of $60.41 million, a P/E ratio of -1.44 and a beta of 1.78.

Alpine Immune Sciences (NASDAQ:ALPN) last issued its quarterly earnings results on Wednesday, November 13th. The biotechnology company reported ($0.62) EPS for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.06. The business had revenue of $0.29 million during the quarter, compared to analysts’ expectations of $0.38 million. On average, sell-side analysts anticipate that Alpine Immune Sciences will post -2.54 earnings per share for the current year.

Institutional investors and hedge funds have recently modified their holdings of the stock. Hikari Power Ltd raised its stake in Alpine Immune Sciences by 52.9% during the third quarter. Hikari Power Ltd now owns 185,587 shares of the biotechnology company’s stock valued at $735,000 after buying an additional 64,224 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Alpine Immune Sciences by 67.7% during the 2nd quarter. Vanguard Group Inc. now owns 202,582 shares of the biotechnology company’s stock worth $853,000 after purchasing an additional 81,800 shares during the period. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Alpine Immune Sciences during the 2nd quarter worth approximately $90,000. Finally, Renaissance Technologies LLC raised its position in shares of Alpine Immune Sciences by 10.8% during the 2nd quarter. Renaissance Technologies LLC now owns 106,261 shares of the biotechnology company’s stock worth $447,000 after purchasing an additional 10,400 shares during the period. 46.80% of the stock is owned by hedge funds and other institutional investors.

About Alpine Immune Sciences

Alpine Immune Sciences, Inc focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202, a programmed cell death protein ligand 1 (PD-L1)/cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antagonist with PD-L1 dependent CD28 costimulation for the treatment of cancer.

See Also: Blue-Chip Stocks

Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.